Evaluation of non-glycemic effects of a fixed combination of alogliptin and pioglitazone

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Background. Due to the unfavorable prognosis in type 2 diabetes mellitus (DM2), priority is given to prescribing hypoglycemic drugs that not only provide optimal glycemic control, but also have pleiotropic effects.

Objective. Evaluation of the non-glycemic benefits of using a fixed combination (FC) of alogliptin and pioglitazone in real clinical practice in diabetic patients who have not achieved carbohydrate metabolism compensation with metformin monotherapy.

Methods. Thirty DM2 patients were examined, including 18 men and 12 women, aged 22 to 72 years (mean age 50.9 ± 11.4 years). Anthropometric parameters, glycated hemoglobin levels, fasting plasma glucose, postprandial glucose, lipid spectrum parameters were assessed; glomerular filtration rate (GFR) and the liver fibrosis index were calculated. The analyzed parameters were recorded initially and 6 months after adding of FC alogliptin 25 mg and pioglitazone 30 mg to metformin (average dose 2000 mg/day).

Results. After 6 months, treatment with FC of alogliptin and pioglitazone resulted in an effective decrease in glycemic control and peripheral tissue insulin resistance, favorable changes in lipid metabolism with a positive effect on the calculated liver fibrosis index and GFR levels.

Conclusion. FC of alogliptin and pioglitazone not only provide optimal glycemic control, but also is capable of exerting a number of pleiotropic effects on cardiovascular diseases and non-alcoholic fatty liver disease.

全文:

受限制的访问

作者简介

O. Elsukova

Kirov State Medical University

Email: nikitinae1991@mail.ru
ORCID iD: 0000-0002-2341-9491
俄罗斯联邦, Kirov

E. Nikitina

Kirov State Medical University

编辑信件的主要联系方式.
Email: nikitinae1991@mail.ru
ORCID iD: 0000-0002-7316-3252

Cand. Sci. (Med.), Associate Professor at the Department of Internal Medicine

俄罗斯联邦, Kirov

参考

  1. Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2023;402(10397):203–34. doi: 10.1016/S0140-6736(23)01301-6.
  2. Остроумова О.Д., Голобородова И.В., Фомина В.М. Сердечно-сосудистые риски у больных сахарным диабетом 2 типа. Кардиоваскулярная терапия и профилактика. 2018;17(4):81–94. [Ostroumova O.D., Goloborodova I.V., Fomina V.М. Cardiovascular risk in type 2 diabetes patients. Cardiovascular Therapy and Prevention. 2018;17(4):81–94. (In Russ.)]. doi: 10.15829/1728-8800-2018-4-81-94.
  3. Салухов В.В., Халимов Ю.Ш., Шустов С.Б. и др. Снижение кардиоваскулярного риска у пациентов с сахарным диабетом 2 типа: обзор основных стратегий и клинических исследований. Сахарный диабет. 2018;21(3):193–205. [Salukhov V.V., Khalimov Yu.Sh., Shustov S.B., et al. Decrease of cardiovascular risk in patients with type 2 diabetes: review of the common strategies and clinical studies. Diabetes Mellitus. 2018;21(3):193–205. (In Russ.)]. doi: 10.14341/DM9570.
  4. Демидова Т.Ю., Кочина А.С. Алоглиптин и пиоглитазон. Перспективы комбинированного применения. Эндокринология: новости, мнения, обучение. 2021;10(4):62–8. [Demidova T.Yu., Kochina A.S. Alogloptin and pioglitazone. Perspectives of combined administration. Endocrinol: News Opin Train. 2021;10(4):62–8. (In Russ.)]. doi: 10.33029/2304-9529-2021-10-4-62-68.
  5. Sterling R.K., Lissen E., Clumeck N., et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317–25. doi: 10.1002/hep.21178.
  6. Петунина Н.А., Гончарова Е.В., Кузина И.А. и др. Роль пиоглитазона в борьбе с инсулинорезистентностью, атеросклерозом, сердечно-сосудистыми заболеваниями и неалкогольной жировой болезнью печени. Сахарный диабет. 2022;25(5):504–13. [Petunina N.A., Goncharova E.V., Kuzina I.A., et al. The role of pioglitazone in the fight against insulin resistance, atherosclerosis, cardiovascular disease, and non-alcoholic fatty liver disease. Diabetes Mellitus. 2022;25(5):504–13. (In Russ.)]. doi: 10.14341/DM12859.
  7. Демидова Т.Ю., Ушанова Ф.О., Жаркова П.О. Гликемические и негликемические преимущества применения фиксированной комбинации алоглиптина и пиоглитазона в управлении сахарным диабетом. FOCUS Эндокринология. 2021;4:39–48. [Demidova Т.Yu., Ushanova F.О., Zharkova P.О. Glycemic and non-glycemic benefits of using the fixed dose combination of alogliptin and pioglitazone in management of diabetes mellitus. FOCUS Endocrinology. 2021;4:39–48. (In Russ.)]. doi: 10.47407/ef2021.2.4.0048.
  8. DeFronzo R.A., Burant C.F., Fleck P., et al. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 Diabetes. J Clin Endocrinol Metab. 2012;97(5):1615–22.
  9. Rosenstock J., Inzucchi S.E., Seufert J., et al. Initial combination therapy with alogliptin and pioglitazone in drug-naive patients with type 2 diabetes. Diab Care. 2010;33(11):2406–8. doi: 10.2337/dc10-0159.
  10. Eliasson B., Möller-Goede D., Eeg-Olofsson K., et al. Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study. Diabetol. 2012;55(4):915–25. doi: 10.1007/s00125-011-2447-3.
  11. ElSayed N.A., Aleppo G., Aroda V.R., et al. Pharmacologic approaches to glycemic treatment: Standards of care in diabetes-2023. Diab Care. 2023;46(Suppl. 1):S140–57. doi: 10.2337/dc23-S009.
  12. Amano Y., Tsuchiya S., Imai M., et al. Combination effects of alogliptin and pioglitazone on steatosis and hepatic fibrosis formation in a mouse model of non-alcoholic steatohepatitis. Biochem Biophys Res Commun. 2018;497(1):207–13. doi: 10.1016/j.bbrc.2018.02.055.
  13. Fioretto P., Frascati A. Role of incretin-based therapies in the treatment of diabetic kidney disease. Diab Mellitus. 2018;21(5):395–8.

补充文件

附件文件
动作
1. JATS XML
下载
2. Fig. 1. Study design

下载 (187KB)
索引源数据
3. Fig. 2. Dynamics of HbA1c, GPN and PPG levels in patients with DM2 treated with alogliptin and pioglitazone

下载 (40KB)
索引源数据
4. Fig. 3. Dynamics of pSCF level in patients treated with alogliptin and pioglitazone

下载 (28KB)
索引源数据

版权所有 © Bionika Media, 2024